$3.670
+0.061 (+1.66%)At close
GNPX News
GNPX Events
Genprex Collaborates with Roche Diagnostics to Validate Biomarkers for NSCLC
Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. The collaboration leverages Roche Diagnostics' expertise in assay development. Roche Diagnostics received U.S. FDA Breakthrough Device Designation for the first AI-driven companion diagnostic for NSCLC that uses a TROP2 score to evaluate NSCLC specimens, and Genprex will use the same antibody against TROP2 for its validation studies. This strategic alignment ensures consistency and builds upon established diagnostic methods. Genprex is expanding on its preclinical and clinical studies to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies. Roche Diagnostics will perform the necessary assay validation using its TROP2 antibody. Genprex anticipates completing these validation studies by approximately the end of 2026, with subsequent integration into its NSCLC clinical program shortly thereafter, dependent on the results of the validation studies. This collaboration exemplifies Genprex's commitment to delivering innovation that enables more precise diagnosis and treatment strategies in oncology, ultimately aiming to improve outcomes for NSCLC patients.
Genprex Trading Halted, News Pending
Genprex trading halted, news pending
Genprex Receives Patent Allowance for Reqorsa Gene Therapy in Canada
Genprex announced that The Canadian Intellectual Property Office has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa Gene Therapy in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer and small cell lung cancer. This patent will expand on the previously granted patents for REQORSA in combination with PD-1 and PD-L1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore Europe, Korea, Australia and Israel.
Genprex Files $250M Mixed Securities Shelf
Genprex files $250M mixed securities shelf
Genprex's Diabetes Gene Therapy Shows Positive Preclinical Data
Genprex's research collaborators presented positive preclinical data on the company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene therapy can reverse hyperglycemia in Type 2 diabetic mouse models. At two and/or four weeks after surgery, researchers performed intraperitoneal glucose tolerance testing or IPGTT, insulin tolerance testing or ITT, glucose-stimulated insulin secretion or GSIS, calculated HOMA-IR and assessed glucagon secretion. The results at four weeks showed major improvements in the control of diabetes. At four weeks after surgery, ex-vivo glucose-stimulated insulin secretion showed that islets isolated from HFD+CMV-PM-GFP treated mice had insulin secretion similar to islets from RD mice, and both groups had increased insulin secretion compared to islets from the control HFD groups, indicating improved beta-cell function with PM treatment. PM gene therapy reverses hyperglycemia, likely in large part by specifically enhancing beta-cell function and maturation. This approach is technically translatable to humans using endoscopic retrograde cholangiopancreatography to deliver PM gene therapy to the pancreas.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.